Lan Yuru,Zhou Jiangyuan,Qiu Tong,et al.Advances in research on the treatment of complicated vascular diseases with sirolimus[J].Journal of Clinical Pediatric Surgery,2024,(07):693-696.[doi:10.3760/cma.j.cn101785-202202017-017]
西罗莫司治疗复杂性脉管异常的研究进展
- Title:
- Advances in research on the treatment of complicated vascular diseases with sirolimus
- Keywords:
- Complicated Vascular Anomalies; Sirolimus; Mammalian Target of Rapamycin; Surgical Procedures; Operative; Child
- 摘要:
- 脉管异常是一类起源于血管和(或)淋巴管的异常疾病的总称,多为良性或交界性病变。脉管异常的治疗方法多样,但对于同时累及多个器官或系统、对机体造成严重功能障碍甚至威胁生命的复杂性/难治性脉管异常而言,传统治疗方法可能疗效较差。西罗莫司是一种雷帕霉素靶蛋白抑制剂,近年来研究发现西罗莫司对于部分复杂性脉管异常疗效较好。本文就西罗莫司治疗复杂性脉管异常的研究进展进行综述。
- Abstract:
- Vascular anomalies are a group of diseases originating from abnormal blood vessels and/or lymphatic vessels,mostly benign or borderline lesions.There are various treatment methods for vascular anomalies,but traditional treatments may be less effective for complicated/refractory vascular anomalies that involve multiple organs or systems,causing severe functional impairment or even life-threatening conditions.Sirolimus,a mammalian target of rapamycin inhibitor,has been found in recent studies to be effective for some complicated vascular anomalies.This article reviews the advances in research on the treatment of complicated vascular anomalies with sirolimus.
参考文献/References:
[1] International Society for the Study of Vascular Anomalies.ISSVA classification for vascular anomalies.[2022-03-15].https:// issva.org/classification.
[2] Sadick M,Müller-Wille R,Wildgruber M,et al.Vascular anomalies (part I):classification and diagnostics of vascular anomalies[J].Rofo,2018,190(9):825-835.DOI:10.1055/a-0620-8925.
[3] Van Damme A,Seront E,Dekeuleneer V,et al.New and emerging targeted therapies for vascular malformations[J].Am J Clin Dermatol,2020,21(5):657-668.DOI:10.1007/s40257-020-00528-w.
[4] Ji Y,Chen SY,Yang KY,et al.Kaposiform hemangioendothelioma:current knowledge and future perspectives[J].Orphanet J Rare Dis,2020,15(1):39.DOI:10.1186/s13023-020-1320-1.
[5] Adams DM,Ricci KW.Vascular anomalies:diagnosis of complicated anomalies and new medical treatment options[J].Hematol Oncol Clin North Am,2019,33(3):455-470.DOI:10.1016/j.hoc.2019.01.011.
[6] Ji Y,Chen SY,Yang KY,et al.A prospective multicenter study of sirolimus for complicated vascular anomalies[J].J Vasc Surg,2021,74(5):1673-1681.e3.DOI:10.1016/j.jvs.2021.04.071.
[7] Cho YJ,Kwon H,Kwon YJ,et al.Effects of sirolimus in the treatment of unresectable infantile hemangioma and vascular malformations in children:a single-center experience[J].J Vasc Surg Venous Lymphat Disord,2021,9(6):1488-1494.DOI:10.1016/j.jvsv.2021.03.014.
[8] Freixo C,Ferreira V,Martins J,et al.Efficacy and safety of sirolimus in the treatment of vascular anomalies:a systematic review[J].J Vasc Surg,2020,71(1):318-327.DOI:10.1016/j.jvs.2019.06.217.
[9] Harbers VEM,Rongen GAPJM,van der Vleuten CJM,et al.Patients with congenital low-flow vascular malformation treated with low dose sirolimus[J].Adv Ther,2021,38(6):3465-3482.DOI:10.1007/s12325-021-01758-y.
[10] Gabeff R,Boccara O,Soupre V,et al.Efficacy and tolerance of sirolimus (rapamycin) for extracranial arteriovenous malformations in children and adults[J].Acta Derm Venereol,2019,99(12):1105-1109.DOI:10.2340/00015555-3273.
[11] Geeurickx M,Labarque V.A narrative review of the role of sirolimus in the treatment of congenital vascular malformations[J].J Vasc Surg Venous Lymphat Disord,2021,9(5):1321-1333.DOI:10.1016/j.jvsv.2021.03.001.
[12] Wiegand S,Wichmann G,Dietz A.Treatment of lymphatic malformations with the mTOR inhibitor sirolimus:a systematic review[J].Lymphat Res Biol,2018,16(4):330-339.DOI:10.1089/lrb.2017.0062.
[13] Boutouja F,Stiehm CM,Platta HW.mTOR:a cellular regulator interface in health and disease[J].Cells,2019,8(1):18.DOI:10.3390/cells8010018.
[14] Rodriguez-Laguna L,Agra N,Iba?ez K,et al.Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly[J].J Exp Med,2019,216(2):407-418.DOI:10.1084/jem.20181353.
[15] Ren AA,Snellings DA,Su YS,et al.PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism[J].Nature,2021,594(7862):271-276.DOI:10.1038/s41586-021-03562-8.
[16] Parker VER,Keppler-Noreuil KM,Faivre L,et al.Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum[J].Genet Med,2019,21(5):1189-1198.DOI:10.1038/s41436-018-0297-9.
[17] Gurunathan A,Ricci K,Iacobas I,et al.Impact of vascular anomalies on the PTEN phenotype in children and young adults[J].Pediatr Blood Cancer,2020,67(6):e28258.DOI:10.1002/pbc.28258.
[18] Queisser A,Seront E,Boon LM,et al.Genetic basis and therapies for vascular anomalies[J].Circ Res,2021,129(1):155-173.DOI:10.1161/CIRCRESAHA.121.318145.
[19] Pang C,Lim CS,Brookes J,et al.Emerging importance of molecular pathogenesis of vascular malformations in clinical practice and classifications[J].Vasc Med,2020,25(4):364-377.DOI:10.1177/1358863X20918941.
[20] Marcoux S,Théorêt Y,Dubois J,et al.Systemic,local,and sclerotherapy drugs:What do we know about drug prescribing in vascular anomalies?[J].Pediatr Blood Cancer,2021,68(12):e29364.DOI:10.1002/pbc.29364.
[21] Adams DM,Trenor CC 3rd,Hammill AM,et al.Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies[J].Pediatrics,2016,137(2):e20153257.DOI:10.1542/peds.2015-3257.
[22] Hammer J,Seront E,Duez S,et al.Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations:a monocentric prospective phase II study[J].Orphanet J Rare Dis,2018,13(1):191.DOI:10.1186/s13023-018-0934-z.
[23] Ji Y,Chen SY,Peng SH,et al.Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma:similarities and differences[J].Orphanet J Rare Dis,2019,14(1):165.DOI:10.1186/s13023-019-1147-9.
[24] Venot Q,Blanc T,Rabia SH,et al.Targeted therapy in patients with PIK3CA-related overgrowth syndrome[J].Nature,2018,558(7711):540-546.DOI:10.1038/s41586-018-0217-9.
[25] Grenier PO,McCormack L,Alshamekh SA,et al.Mucocutaneous adverse events associated with oral sirolimus for the treatment of vascular anomalies[J].JAMA Dermatol,2021,157(2):233-235.DOI:10.1001/jamadermatol.2020.5180.
[26] 树叶,谈鑫,刘向宇,等.口服西罗莫司治疗小儿脉管异常类疾病的效果观察[J].临床小儿外科杂志,2021,20(11):1064-1069.DOI:10.12260/lcxewkzz.2021.11.013. Shu Y,Tan X,Liu XY,et al.Study of oral sirolimus in the treatment of vascular anomaliesin infants and children[J].DOI:10.12260/lcxewkzz.2021.11.013.
[27] Ying HR,Qiao CZ,Yang X,et al.A case report of 2 sirolimus-related deaths among infants with kaposiform hemangioendotheliomas[J].Pediatrics,2018,141(Suppl 5):S425-S429.DOI:10.1542/peds.2016-2919.
[28] Mizuno T,Fukuda T,Emoto C,et al.Developmental pharmacokinetics of sirolimus:implications for precision dosing in neonates and infants with complicated vascular anomalies[J].Pediatr Blood Cancer,2017,64(8):e26470.DOI:10.1002/pbc.26470.
[29] Ji Y,Chen SY,Zhou JY,et al.Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma:a randomized clinical trial[J].Blood,2022,139(11):1619-1630.DOI:10.1182/blood.2021014027.
[30] Lackner H,Karastaneva A,Schwinger W,et al.Sirolimus for the treatment of children with various complicated vascular anomalies[J].Eur J Pediatr,2015,174(12):1579-1584.DOI:10.1007/s00431-015-2572-y.
[31] Foster JB,Li D,March ME,et al.Kaposiform lymphangiomatosis effectively treated with MEK inhibition[J].EMBO Mol Med,2020,12(10):e12324.DOI:10.15252/emmm.202012324.
[32] Barclay SF,Inman KW,Luks VL,et al.A somatic activating NRAS variant associated with kaposiform lymphangiomatosis[J].Genet Med,2019,21(7):1517-1524.DOI:10.1038/s41436-018-0390-0.
[33] Li D,March ME,Gutierrez-Uzquiza A,et al.ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor[J].Nat Med,2019,25(7):1116-1122.DOI:10.1038/s41591-019-0479-2.
相似文献/References:
[1]树叶,谈鑫,刘向宇,等.口服西罗莫司治疗小儿脉管异常类疾病的效果观察[J].临床小儿外科杂志,2021,20(11):1064.[doi:10.12260/lcxewkzz.2021.11.013]
Shu Ye,Tan Xin,Liu Xiangyu,et al.Study of oral sirolimus in the treatment of vascular anomaliesin infants and children[J].Journal of Clinical Pediatric Surgery,2021,20(07):1064.[doi:10.12260/lcxewkzz.2021.11.013]
[2]丁颖菁,李凯.西罗莫司在小儿卡波西型血管内皮瘤中的应用进展[J].临床小儿外科杂志,2022,21(10):987.[doi:10.3760/cma.j.cn101785-202008017-015]
Ding Yingjing,Li Kai.Current applications and future perspectives of sirolimus in the treatment of kaposiform hemangioendothelioma[J].Journal of Clinical Pediatric Surgery,2022,21(07):987.[doi:10.3760/cma.j.cn101785-202008017-015]
[3]李楠,王健俊,黄昭榕,等.婴儿肝门部血管内皮瘤合并Kasabach-Merritt综合征引起胆道梗阻1例及文献复习[J].临床小儿外科杂志,2023,22(05):471.[doi:10.3760/cma.j.cn101785-202202001-013]
Li Nan,Wang Jianjun,Huang Zhaorong,et al.Infant hepatic hilar hemangioendothelioma plus Kasabach-Merritt syndrome causing biliary obstruction:one case report and literature review[J].Journal of Clinical Pediatric Surgery,2023,22(07):471.[doi:10.3760/cma.j.cn101785-202202001-013]
备注/Memo
收稿日期:2022-2-7。
基金项目:国家自然科学基金项目(82273556);四川省科技厅重点研发项目(2022YFS0233、2022YFS0225);四川大学从0到1创新研究项目(2022SCUH0033);四川大学医学+信息中心交叉学科建设开放项目(YGJC004);四川大学华西医院学科卓越发展1·3·5工程临床研究孵化项目(2019HXFH056、2020HXFH048);四川大学华西医院学科卓越发展1·3·5工程交叉学科创新项目(ZYJC21060)
通讯作者:吉毅,Email: